Market Flux
Open the Terminal

Most Active

EyePoint Pharmaceuticals Plunges 65% After DURAVYU Fails Phase 3 Non-Inferiority Test in Wet AMD

By Market Flux··1 min read

EyePoint Pharmaceuticals, Inc. $EYPT

$4.87-67.02%as of publication

5D Change
-62.78%
Notional
$247.18M

EyePoint Pharmaceuticals shares cratered more than 65% in premarket trading on August 17, hitting a 52-week low of $4.06, after the company's Phase 3 LUGANO trial for DURAVYU in wet age-related macular degeneration failed to meet its primary endpoint of non-inferiority versus aflibercept. The miss was driven by vision loss in just 9 of the 211 patients in the full dataset, a narrow margin that nonetheless proved decisive in the statistical outcome. The failure drew negative analyst commentary from Cantor Fitzgerald and JPMorgan, adding institutional pressure to the selloff.

Rival ocular drug developer Ocugen gained 12.6% in premarket trading on the news, reflecting a competitive shift in the wet AMD treatment landscape. Unusual options activity in EYPT also spiked during the session.

© AI-generated summary is provided by Market Flux

Sources

  1. reuters.comEyePoint's eye drug misses main goal in late-stage trial
  2. Wallstengine$EYPT PHASE 3 TRIAL MISSES PRIMARY ENDPOINT EyePoint said its Phase 3 LUGANO trial for DURAVYU in wet AMD failed to meet the primary endpoint of non-inferiority versus aflibercept in the full dataset. The company said the miss was driven by 9 of 211 patients who had vision loss
  3. OpenOutcrier$EYPT (-65.4% pre) EyePoint’s DURAVYU misses primary endpoint in wet AMD trial
  4. InvestingEyepoint Pharmaceuticals stock hits 52-week low at $4.06
  5. MarketRebelsIncreasing unusual option volume: $IHI $EYPT $FTI $DHT $AS $LTH $CAPR $ICLN $RARE $BZAI $MAT $FOXA